Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections

Journal of Antibiotics

Volumn 70, Issue 4, 2017, Pages 386-394

  Brown, Pamela ^a   Dawson, Michael J ^a  

^a BioPark Hertfordshire   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CB 182 804; LIPOPEPTIDE; NAB 741; NONAPEPTIDE; POLYMYXIN B; POLYMYXIN DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; POLYMYXIN;

ANTIBIOTIC SENSITIVITY; DRUG MECHANISM; DRUG SYNTHESIS; GRAM NEGATIVE INFECTION; HUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; SYNTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 85016260606     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2016.146     Document Type: Review

References (79)

1. Ainsworth, G. C., Brown, A. M. & Brownlee, G. Aerosporin, an antibiotic produced by Bacillus aerosporus Greer. Nature 159, 263 (1947).
2. Stansly, P. G., Shepherd, R. G. & White, H. J. Polymyxin: a new chemotherapeutic agent. Bull. Johns Hopkins Hosp. 81, 43-54 (1947).
3. Schoenbach, E. B. & Bryer, M. J. The clinical use of polymyxin. Bull. Johns Hopkins Hosp. 82, 637-639 (1948).
4. Li, J. et al. Colistin: the re-emerging antibiotic for multi-drug resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6, 589-601 (2006).
5. Landman, D., Georgescu, C., Martin, D. A. & Quale, J. Polymyxins revisited. Clin. Microbiol. Rev. 21, 449-465 (2008).
6. Lim, L. M. et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30, 1279-1291 (2010).
7. Liu, Y. Y. et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16, 161-168 (2016).
8. Sader, H. S., Farrell, D. J., Flamm, R. K. & Jones, R. N. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European Hospitals (2009-2011). Diagn. Microbiol. Infect. Dis. 78, 443-448 (2014).
9. Nation, R. L., Velkov, T. & Li, J. Colistin and Polymyxin B: peas in a pod or chalk and cheese? Clin. Infect. Dis. 59, 88-94 (2014).
10. Elias, L. S., Konzen, D., Krebs, J. M. & Zavascki, A. P. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J. Antimicrob. Chemother. 65, 2231-2237 (2010).
11. Nation, R. L. et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet. Infect. Dis. 15, 225-234 (2015).
12. Rao, G. G. et al. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob. Agents Chemother. 58, 1381-1388 (2014).
13. Bergen, P. J. et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rational use. Pharmacotherapy 35, 34-42 (2015).
14. Vaara, M. Polymyxins and their novel derivatives. Curr. Opin. Microbiol. 13, 574-581 (2010).
15. Vaara, M. Novel derivatives of polymyxins. J. Antimicrob. Chemother. 68, 1213-1219 (2013).
16. Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure-activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898-1916 (2010).
17. Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E. & Li, J. Pharmacology of polymyxins: new insights into an "old" class of antibiotics. Future Microbiol. 8(6), 711-724 (2013).
18. Kadar, B., Kocis, B., Nagy, K. & Szabo, D. The Renaissance of polymyxins. Curr. Med. Chem. 20, 3759-3773 (2013).
19. Orwa, J. A. et al. Isolation and structural characterisation of Polymyxin B components. J. Chromatogr. A 912, 369-373 (2001).
20. Kline, T., Holub, D., Therrien, J., Leung, T. & Ryckman, D. Synthesis and characterisation of the colistin peptide polymyxin E1 and related peptides. J. Peptide Res. 57, 175-187 (2001).
21. Shoji, J., Kato, T. & Hinoo, H. The structure of polymyxin S. (Studies on antibiotics from the genus Bacillus. XXI). J. Antibiot. 30, 1035-1041 (1977).
22. Martin, N. I. et al. Isolation, structural characterisation and properties of Mattacin (Polymyxin M), a cyclic peptide antibiotic produced by Paenobacillus kobensis M. J. Biol. Chem. 278(15), 13124-13132 (2003).
23. Shaheen, M., Li, J., Ross, A. C., Vederas, J. C. & Jensen, S. E. Paenibacillus polymyxa PKB1 produces variants of Polymyxin B-Type Antibiotics. Chem. Biol. 18, 1640-1648 (2011).
24. Shoji, J., Kato, T. & Hinoo, H. The structure of Polymyxin T1 (Studies on antibiotics from the genus Bacillus XXII). J. Antibiot. 30(12), 1042-1048 (1977).
25. Storm, D. R., Rosenthal, K. S. & Swanson, P. E. Polymyxin and related peptide antibiotics. Ann. Rev. Biochem. 46, 723-763 (1977).
26. Rosenthal, K. S., Ferguson, R. A. & Storm, D. R. Mechanism of action of EM49, membrane-active peptide antibiotic. Antimicrob. Agents Chemother. 12(6), 665-672 (1977).
27. Parker, W. L. & Rathnum, M. L. EM49, a new peptide antibiotic IV. The structure of EM49. J. Antibiot. 28, 379-389 (1975).
28. Shoji, J. et al. Isolation of a new antibiotic 333-25, related to antibiotic EM 49. (Studies on antibiotics from the genus Bacillus. XI). J. Antibiot. 29, 516-520 (1976).
29. Sugawara, K. et al. Bu-2470, a new peptide antibiotic complex. II. Structure determination of Bu-2470A, B1, B2a and B2b. J. Antibiot. 36(6), 634-638 (1983).
30. Kato, T. & Shoji, J. The structure of octapeptin D (studies on antibiotics from the genus Bacillus. XXVIII). J. Antibiot. 33(2), 186-191 (1980).
31. Qian, C.-D. et al. Battacin (Octapeptin B5), a new cyclic lipopeptide antibiotic from paenibacillus tianmuensis active against multidrug-resistant gram-negative bacteria. Antimicrob. Agents Chemother. 56(3), 1458-1465 (2012).
32. De Zoysa, G. H., Cameron, A. J., Hegde, V. V., Raghothama, S. & Saronji, V. Antimicrobial peptides with potential for biofilm eradication: synthesis and structure activity relationship studies of Battacin Peptides. J. Med. Chem. 58, 625-639 (2015).
33. Mares, J., Kumaran, S., Gobbo, M. & Zerbe, O. Interactions of lipopolyssaccharide and polymyxin studied by nmr spectroscopy. J. Biol. Chem. 284, 11498-11506 (2009).
34. Vaara, M. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56, 395-411 (1992).
35. Deris, Z. Z. et al. Probing the penetration of antimicrobial polymyxin lipopeptides into Gram-negative bacteria. Bioconjug. Chem. 25, 750-760 (2014).
36. Kelesidis, T. & Falagas, M. E. The safety of polymyxin antibiotics. Exp. Opin. Drug Safety 14, 1687-1701 (2015).
37. Justo, J. A. & Bosso, J. A. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 35, 28-33 (2015).
38. Phe, K. et al. In vitro assessment and multi center color study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob. Agents Chemother. 58, 2740-2746 (2014).
39. Rigatto, M. H. et al. Multicenter prospective color study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob. Agents Chemother. 60, 2443-2449 (2016).
40. Azad, M. A. K., Akter, J., Rogers, K. L., Nation, R. L. & Li, J. Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells. Antimicrob. Agents Chemother. 59, 2136-2143 (2015).
41. Vaara, M. et al. Novel Polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 52(9), 3229-3236 (2008).
42. Huang, J. X. et al. Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity; comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells. Pharmacol. Res. Perspect. 3, e00148 (2015)
43. Olaitan, A. O., Morand, S. & Rolain, J. M. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front. Microbiol. 5, 643 (2014).
44. Sharma, S. K. et al. Solid-Phase total synthesis of Polymyxin B1. J. Pept. Res. 53, 501-506 (1999).
45. Velkov, T. et al. Teaching 'old' Polymyxins new tricks: new-generation lipopeptides targeting Gram-negative 'superbugs'. ACS Chem. Biol. 9(5), 1172-1177 (2014).
46. Kanazawa, K. et al. Contribution of each amino acid residue in Polymyxin B3 to antimicrobial and lipopolysaccharide binding activity. Chem. Pharm. Bull. 57, 240-244 (2009).
47. Ramesh, S., Govender, T., Kruger, H. G., Alberico, F. & de la Torre, B. G. An improved and efficient strategy for the total synthesis of a colistin-like peptide. Tetrahedron Lett. 57, 1885-1888 (2016).
48. De Visser, P. C. et al. Solid-phase synthesis of polymyxin B1 and analogues via a safetycatch approach. J. Pept. Res. 61, 298-306 (2003).
49. Magee, T. V. et al. Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections. J. Med. Chem. 56, 5079-5093 (2013).
50. Xu, W.-L. et al. A new strategy for the total solid-phase synthesis of polymyxins. Tetrahedron Lett. 56, 4796-4799 (2015).
51. Gallardo-Godoy, A. et al. Activity and predicted nephrotoxicity of Synthetic Antibiotics based on Polymyxin B. J. Med. Chem. 59(3), 1068-1077 (2016).
52. Weinstein, J., Afonso, A., Moss, E. & Miller, G. Selective chemical modifications of Polymyxin B. BioOrg. Med. Chem. Lett. 8, 3391-3396 (1998).
53. Kimura, Y., Matsunaga, H. & Vaara, M. Polymyxin B octapeptide and Polymyxin B heptapeptide are potent outer membrane permeability-increasing agents. J. Antibiot. 45, 742-749 (1992).
54. Okimura, K., Ohki, K., Sato, Y., Ohnishi, K. & Sakura, N. Semi-synthesis of Polymyxin B (2-10) and Colistin (2-10) analogs employing the Trichloroethoxycarbonyl (Troc) group for side chain protection of α, γ-diaminobutyric acid residues. Chem. Pharm. Bull. 55 (12), 1724-1730 (2007).
55. O'Dowd, H. et al. Preparation of tetra-BOC protected polymyxin B nonapeptide. Tetrahedron Lett. 48, 2003-2005 (2007).
56. Leese, R. A. (BioSource Pharm. Inc.) Antibiotic compositions for the treatment of Gram Negative Infections. WO2010075416 (2010).
57. Fauchere, J. L. & Mosbach, K. Production of Covalently-linked Conjugates from an Antibiotic and a Non-toxic derivative of Polymyxin B. WO8800950 (1988).
58. Chen, J. M., Li, Z. B., Magee, T. V. & Martinez, C. A. (Pfizer Inc.) Polymyxin derivatives useful as antibacterial agents. WO2012168820 (2012).
59. Brown, P. et al. Poster F-739, 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, CA, USA, 2015).
60. Vaara, M. & Vaara, T. Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide. Nature 303, 526-528 (1983).
61. Keirstead, N. D. et al. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol. Sci. 137, 278-291 (2014).
62. Vaara, M. et al. A novel Polymyxin derivative that lacks the fatty acyl tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob. Agents Chemother. 54, 3341-3346 (2010).
63. Okimura, K. et al. Chemical conversion of natural polymyxin B and colistin to their N-terminal derivatives. Bull. Chem. Soc. Jpn. 80, 543-552 (2007).
64. Coleman, S., Bleavins, M., Lister, T., Vaara, M. & Parr, T. J. The Assessment of SPR741 for Nephrotoxicity in Cynomolgus Monkeys and Sprague-Dawley rats. Poster Monday- 523 (ASM Microbe, Boston, MA, USA, 2016).
65. Katsuma, N. et al. Development of des-fatty acyl-Polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity. Chem. Pharm. Bull. 57, 332-336 (2009).
66. Sato, Y., Shindo, M., Sakura, N., Uchida, Y. & Kato, I. Novel des-fatty acyl Polymyxin B derivatives with Pseudomonas aeruginosa-specific antimicrobial activity. Chem. Pharm. Bull. 59, 597-602 (2011).
67. Quale, J. et al. Activity of Polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City. Microb. Drug Resist. 18, 132-136 (2012).
68. Arya, A. et al. Poster F1-1627, 50th Intersci. Conf. Antimicrob. Agents Chemother. (Boston, USA, 2010).
69. Coleman, S., Deats, T., Pawliuk, R., Chavan, A. & Oleson, F. Poster F-1630, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (Boston, MA, USA, 2010).
70. Vaara, M. et al. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 52, 3229-3236 (2008).
71. Vaara, M. & Vaara, T. Structure-activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides 31, 2318-2321 (2010).
72. Vaara, M., Sader, H. S., Rhomberh, P. R., Jones, R. N. & Vaara, T. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. J. Antimicrob. Chemother. 68, 636-639 (2013).
73. Mingeot-Leclerq, M. P., Tulkens, P. M., Denamur, S., Vaara, T. & Vaara, M. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides 35, 248-252 (2012).
74. Vaara, M. & Vaara, T. The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubule cells. Int. J. Antimicrob. Agents 41, 292-293 (2013).
75. Ali, F. E. A. et al. Pharmacokinetics of novel antimicrobial cationic peptides NAB7061 and NAB739 in rats following intravenous administration. J. Antimicrob. Chemother. 64, 1067-1070 (2009).
76. Wiederhold, N. P. et al. Poster F-734, 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, CA, USA,2015).
77. Boakes, S. et al. Poster F-735, 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, CA, USA, 2015).
78. Li, J., Nation, R., Velkov, T., Thompson, P. & Roberts, K. D. (Monash University). Polymyxin derivatives as antimicrobial compounds. WO2015149131 (2015).
79. Sabet et al. Pharmacology of the Novel Polymyxin Faddi-287 in Preclinical Models. Poster Saturday-499 (ASM Microbe, Boston, MA, USA, 2016).